Specialty Chemical Stock Receives Prestigious ‘One Star Export House’ Status From GoI

The manufacture, sourcing, and distribution of chemicals and pharmaceutical products are the main objectives of Sudarshan Pharma Industries Limited (SPIL), an Indian pharmaceutical corporation. Following the company's announcement on Wednesday that it had been granted a certificate of recognition One Star Export House by the Directorate General of Foreign Trade of the Department of Commerce, Ministry of Commerce and Industry, Government of India, the small-cap stock in the specialty chemical sector is expected to be the focus of attention. The certificate will be valid for five years, from May 8, 2025, to March 31, 2028.

The stock was trading at a 3% lower circuit limit at Rs 30.38 a share with a market capitalization of Rs 731.12 Cr at 12:16 IST on Thursday, June 6.

Additionally, the company has declared that Thursday, June 12, 2025, will be the day of its Extraordinary General Meeting (EGM). "The remote e-voting period begins on Monday, 9th June, 2025 at 9:00 a.m. and ends on Wednesday, 11th June, 2025 at 5:00 p.m. The remote e-voting module shall be disabled by NSDL for voting thereafter. The Members, whose names appear in the Register of Members / Beneficial Owners as on the record date (cut-off date) i.e. Thursday, 5th June, 2025 may cast their vote electronically. The voting right of shareholders shall be in proportion to their share in the paid-up equity share capital of the Company as on the cut-off date, being Thursday, 5th June 2025," said Sudarshan Pharma in a stock exchange filing.

For the bulk drug industry, the central government has set aside Rs 100 billion. Of this, Rs 30 billion will be used to promote bulk drug 3 parks over the next five years, and Rs 69.4 billion will be used for a production-linked incentive scheme that will encourage the nation's domestic production of critical KSMs, drug intermediates, and APIs over the next eight years. Since the majority of the 53 vital APIs/intermediates that the scheme identified are utilized to generate crucial medications and since India is heavily dependent on China, Sudarshan Pharma is establishing a manufacturing facility to produce a small number of the critical APIs that China imports.

Dr. William Selvamurthy of Amity University, a renowned pioneer in global education, recently partnered with SPIL in a strategic relationship. The Amity University, Noida campus has officially acknowledged this collaboration, which includes the following important areas: cooperation in pharmaceutical and healthcare research and development (R&D), joint initiatives in nanotechnology, collaboration in patent writing and submission processes, commercialization of innovative technologies and R&D products, and participation in clinical studies and patent filings.

"The Company is continuously focusing on increase in exports and manufacturing sales and even working on to maximize its profit margin on resale of API in local markets, therefore, there is substantial growth in EBITDA margin in H2FY25 and consequently, the Company has achieved substantial growth in PAT for the same period," Sudarshan Pharma Industries said in a statement in terms of its financial health in FY25.

Sudarshan Pharma Share Price Target

"Sudarshan Pharma stock price is bearish on the Daily charts with strong resistance at 31.22. A Daily close below support of 28.8 could lead to a target of 25 in the near term," commented A R Ramachandran, independent research analyst.

Sudarshan Pharma Industries Limited (SPIL) was established in 2008 and is involved in the production and sourcing of pharmaceutical and chemical goods. The company has established a foothold in both international and Indian markets with foreign export market includes UK, Australia, Uzbekistan, Syria, Oman, Taiwan, and the MENA. Intas, Minova, Invision Life Sciences, Omkar Pharma, SRF, Astral Pipes, DuPont, Reliance, Bayer Corp, Akzo Nobel, and others are important clients of pharmaceutical formulations and specialized chemicals.